Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,276 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Completed Phase 3 Interventional Results available

Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

NCT01025336
View directory record Official record
Conditions
Healthy
Interventions
Blood draw
Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Chandler, Arizona • Phoenix, Arizona • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

NCT01112527
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme
Interventions
PF-00299804
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

NCT04171141
View directory record Official record
Conditions
Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
Interventions
PF-07062119, Anti-PD1, Anti-VEGF
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

NCT00201773
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Celecoxib, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 27, 2026, 8:12 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

NCT07269301
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01270971
View directory record Official record
Conditions
Onychomycosis of Toenails
Interventions
AN2690 Topical Solution, 5%, Solution Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Burbank, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 27, 2026, 8:12 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer

NCT00090701
View directory record Official record
Conditions
Lung Neoplasms
Interventions
AG2037
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
4
States / cities
Poway, California • Washington D.C., District of Columbia • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00498602
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
27
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

NCT00205777
View directory record Official record
Conditions
Osteoporosis
Interventions
Bazedoxifene Acetate, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
7,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
205
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

NCT00418145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
megadose oral methylprednisolone, IV methylprednisolone
Drug
Lead sponsor
Fred Lublin
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
10
States / cities
New Brunswick, New Jersey • Brooklyn, New York • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Results available

A Study Of PF-04449913 Administered Alone In Select Solid Tumors

NCT01286467
View directory record Official record
Conditions
Solid Tumors
Interventions
PF-04449913
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional

Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

NCT00440492
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PLA-695
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

NCT01526057
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-05280586, MabThera, Rituxan
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 27, 2026, 8:12 AM EDT
Completed No phase listed Observational

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

NCT01128439
View directory record Official record
Conditions
Invasive Pneumococcal Disease
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 2 Interventional Results available

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

NCT00982657
View directory record Official record
Conditions
Solid Tumor
Interventions
CVX-060 + sunitinib, Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Santa Monica, California • Southaven, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

NCT06369454
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 4 Interventional Results available

A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

NCT01370356
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Encino, California • Newport Beach, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional

Study Evaluating IMA-638 in Asthma

NCT00339872
View directory record Official record
Conditions
Asthma
Interventions
IMA-638
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of the Effect of Dietary Fat Type and Amount on Vitamin D3 Absorption

NCT01508845
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
cholecalciferol
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

NCT05632354
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Baton Rouge, Louisiana • New Orleans, Louisiana • Madison, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

NCT01819922
View directory record Official record
Conditions
Healthy
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 1 Interventional

PF-07284892 in Participants With Advanced Solid Tumors

NCT04800822
View directory record Official record
Conditions
Solid Tumor
Interventions
PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Not applicable Interventional

An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002077
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Chicago, Illinois • Newark, New Jersey • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 27, 2026, 8:12 AM EDT